Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

Bibliographic Details
Main Authors: B. Wake, C. Hyde, S. Bryan, P. Barton, F. Song, A. Fry-Smith, C. Davenport
Format: Article
Language:English
Published: NIHR Journals Library 2002-01-01
Series:Health Technology Assessment
Online Access:https://doi.org/10.3310/hta6030

Internet

https://doi.org/10.3310/hta6030

Similar Items